Back to search

Peptide record

TPDB02919

dLL-37(17-32)c LL-37(17-32)b Antibacterial Anticancer Cell-penetrating Peptides Toxicity standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB02919
dLL-37(17-32)c LL-37(17-32)b
Antibacterial Anticancer Cell-penetrating Peptides Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP dbAMP 3.0 iACP-DRLF CPPsite3.0
standard
No
A 16-aa standard natural multi-activity (Antibacterial, Anticancer, Cell-penetrating Peptides, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FKRIVQRIKDFLRNLV
Physicochemical Analysis
C95H161N29O21
ACEGHMPSTWY
R
2045.51
12.13
5
1
8
+4
2.78
-0.075
133.75
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
0
A
3
R
1
N
1
D
0
C
0
E
1
Q
0
G
0
H
2
I
2
L
2
K
0
M
2
F
0
P
0
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 3 N: 1 D: 1 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 2 L: 2 K: 2 M: 0 F: 2 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
16
C95H161N29O21
2045.51
12.13
+4
2.78
-0.075
Free
L
Linear
Free
Antibacterial
LL-37,a series of peptide fragments
Evidence Records 8 records
Evidence 1 Activity

Activity

LC50
LC50=30 µM
Anticancer
30 µM

Target

Tumor
KBv
Not Available

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

LC50
LC50=30 µM
Anticancer
30 µM

Target

Oral Cancer
KB
Not Available

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 3 Activity

Activity

Not Available
Anticancer

Target

Oral Cancer
KB
Not Available

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 4 Activity

Activity

LC50
LC50=25 µM
Anticancer
25 µM

Target

Prostate Cancer
HBMEC
Not Available

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 5 Activity

Activity

Not Available
Anticancer

Target

Prostate Cancer
HBMEC
Not Available

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 6 Activity

Activity

13.61±3.29% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
13.61±3.29% Hemolysis | 256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Cathelicidin-Derived Synthetic Peptide Improves Therapeutic Potential of Vancomycin Against Pseudomonas aeruginosa. | Front Microbiol | 2019
Evidence 7 Activity

Activity

EC50
Toxicity
>200 µg/mL
Cytotoxic
EC50 | >200 | µg/mL | target cell: Human corneal epithelial cells HCE-2

Target

Human corneal epithelial cells HCE-2

Source & Reference

NA
DBAASP
Cathelicidin-Derived Synthetic Peptide Improves Therapeutic Potential of Vancomycin Against Pseudomonas aeruginosa. | Front Microbiol | 2019
Evidence 8 Activity

Activity

50% Cell death
Toxicity
25±1 µM
Cytotoxic
50% Cell death | 25±1 | µM | target cell: Human brain microvascular endothelial cells HBMEC

Target

Human brain microvascular endothelial cells HBMEC

Source & Reference

NA
DBAASP
Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. | J Am Chem Soc | 2006